The production, characterisation and enhanced pharmacokinetics of scFv–albumin fusions expressed in Saccharomyces cerevisiae
- 27 May 2010
- journal article
- Published by Elsevier in Protein Expression and Purification
- Vol. 73 (2), 113-124
- https://doi.org/10.1016/j.pep.2010.05.009
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- Modulation of Chaperone Gene Expression in Mutagenized Saccharomyces cerevisiae Strains Developed for Recombinant Human Albumin Production Results in Increased Production of Multiple Heterologous ProteinsApplied and Environmental Microbiology, 2008
- Optimization of humanized IgGs in glycoengineered Pichia pastorisNature Biotechnology, 2006
- Phase I Comparability of Recombinant Human Albumin and Human Serum AlbuminThe Journal of Clinical Pharmacology, 2005
- Antibodies and Genetically Engineered Related Molecules: Production and PurificationBiotechnology Progress, 2004
- Characterization of Humanized Antibodies Secreted byAspergillus nigerApplied and Environmental Microbiology, 2004
- Expression of full-length immunoglobulins in Escherichia coli: rapid and efficient production of aglycosylated antibodiesJournal of Immunological Methods, 2002
- Yeast 2 µm plasmid copy number is elevated by a mutation in the nuclear gene UBC4Yeast, 2001
- Recombinant Human Albumin as a Stabilizer for Biological Materials and for the Preparation of International Reference ReagentsBiologicals, 1998
- Disruption of theSaccharomyces cerevisiae YAP3 gene reduces the proteolytic degradation of secreted recombinant human albuminYeast, 1998
- PMT1, the gene for a key enzyme of protein O-glycosylation in Saccharomyces cerevisiae.Proceedings of the National Academy of Sciences, 1993